Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
-
REGULATORY MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
-
BUSINESS Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
-
REGULATORY Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
-
BUSINESS Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
-
REGULATORY Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
-
BUSINESS Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
-
BUSINESS Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
-
BUSINESS 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
-
BUSINESS Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
-
BUSINESS Teva Pharma Japan to Postpone NHI Price Listing of All Generics Including Valsartan in June
May 23, 2014
-
ORGANIZATION Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
-
BUSINESS AZ to Highlight Global Data to Push Forxiga: Primary Care Head
May 21, 2014
-
REGULATORY MHLW, MOF, Cabinet Office to Come to Agreement on Once-yearly NHI Price Revision by End May
May 21, 2014
-
BUSINESS Improper Staffer Involvement in 4 More Japan CML Programs: Novartis
May 20, 2014
-
REGULATORY PIC/S Committee OKs Japan’s Accession from July 2014
May 20, 2014
-
ACADEMIA Sapporo Hospital Sorry for Ethical Guidelines Violations in Nesp Clinical Study
May 19, 2014
-
BUSINESS Jury Finds in Favor of Takeda in Actos Lawsuit, Turning Down Plaintiff’s Claim
May 19, 2014
-
BUSINESS Generic Makers See Softer Sales Growth in FY2013
May 16, 2014
-
BUSINESS Daiichi Sankyo Chair Shoda to Bow Out, Become Adviser
May 16, 2014
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…